Wharton’s Jelly Mesenchymal Stem Cell Administration Improves Quality of Life and Self-Sufficiency in Children with Cerebral Palsy: Results from a Retrospective Study

Table 6

Treatment efficacy in subgroups identified on the basis of minimum total cell dose per kilogram of body mass during the whole treatment course.

Minimum total dose (×10^6/kg)	N	Average QoL response per administration after following administrations; ( chi^2 with Yates correction = not significant)					Developmental breakthrough; ( chi^2 with Yates )						Proportion of patients with developmental breakthrough
		<1				≥4	0	1	2	3	4	5
≤2.89 (<Q1)	14	4	5	4	0	1	12	2	0	0	0	0	0%
2.89-≤4.07 (Q1-Q2)	13	6	3	2	2	0	9	1	2	0	1	0	7.7%
4.07-≤5.0 (Q2-Q3)	16	8	3	3	2	0	8	1	0	5	2	0	43.8%
>5.0(>Q3)	11	5	3	3	0	0	4	1	1	2	3	0	45.5%

QoL: quality of life; Q: quartile. The highest improvement in quality of life between two consecutive assessments. Cells marked in bold represent categorization used in Yates’ chi-square test.